Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Ruxolitinib
Indication
Myelofibrosis, postessential thrombocythaemia, Myelofibrosis, postpolycythaemia vera, Primary myelofibrosis, Polycythemia vera.
Instruction
May be taken with or without food.
Drug interaction
Increased plasma concentration with strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, indinavir, itraconazole, lopinavir, ritonavir, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin,
Malaysia
